7170-58-3Relevant academic research and scientific papers
Synthesis of rigidified eIF4E/eIF4G inhibitor-1 (4EGI-1) mimetic and their in vitro characterization as inhibitors of protein-protein interaction
Mahalingam, Poornachandran,Takrouri, Khuloud,Chen, Ting,Sahoo, Rupam,Papadopoulos, Evangelos,Chen, Limo,Wagner, Gerhard,Aktas, Bertal H.,Halperin, Jose A.,Chorev, Michael
, p. 5094 - 5111 (2014/07/08)
The 4EGI-1 is the prototypic inhibitor of eIF4E/eIF4G interaction, a potent inhibitor of translation initiation in vitro and in vivo and an efficacious anticancer agent in animal models of human cancers. We report on the design, synthesis, and in vitro ch
NOVEL ARYL UREA DERIVATIVE
-
Page/Page column 61, (2012/11/13)
There is a need for FAAH inhibitors capable of oral administration and having excellent efficacy, particularly agents for the prevention and treatment of pain. Disclosed are novel arylurea compounds represented by formula (I), salts or solvates thereof, and pharmaceutical compositions comprising the same as an active ingredient. The pharmaceutical composition is used primarily for FAAH inhibitors, or agents for prevention and treatment of pain.
COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION
-
Page/Page column 99-100, (2012/02/01)
Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.
